1. Home
  2. GAIA vs GLSI Comparison

GAIA vs GLSI Comparison

Compare GAIA & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gaia Inc.

GAIA

Gaia Inc.

HOLD

Current Price

$3.72

Market Cap

105.7M

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$17.21

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAIA
GLSI
Founded
1988
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.7M
123.9M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
GAIA
GLSI
Price
$3.72
$17.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$9.00
$39.00
AVG Volume (30 Days)
133.7K
373.1K
Earning Date
11-03-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$98,622,000.00
N/A
Revenue This Year
$11.55
N/A
Revenue Next Year
$11.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.80
N/A
52 Week Low
$2.93
$7.78
52 Week High
$6.39
$17.99

Technical Indicators

Market Signals
Indicator
GAIA
GLSI
Relative Strength Index (RSI) 42.49 87.38
Support Level $3.39 $13.11
Resistance Level $4.05 $13.76
Average True Range (ATR) 0.27 1.48
MACD 0.05 0.69
Stochastic Oscillator 43.96 91.51

Price Performance

Historical Comparison
GAIA
GLSI

About GAIA Gaia Inc.

Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an International presence.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: